Sfoglia per AUTORE
NANNI M
Collezione AO Ordine Mauriziano

  

Items : 4

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

Efficacy and safety of front-line treatment with ibrutinib and rituximab in unfit patients with chronic lymphocytic leukemia (CLL). First report of the GIMEMA LLC1114 study in Haematologica

2019
ASL Asti
AO Ordine Mauriziano

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati M; Gottardi D; Re F; Ilariucci F; Zinzani PL; Mannina D; Gozzetti A; Molinari AL; Gentile M; Chiarenza A; Laurenti L; Varettoni M; Ibatici A; Murru R; Tani M; et alii...

Ibrutinib and rituximab as front-line treatment for unfit patients with chronic lymphocytic leukemia (CLL). preliminary results from the Gimema LLC1114 study in HemaSphere

2019
AO Ordine Mauriziano
ASL Asti

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati AM; Gottardi D; Re F; Ilariucci F; Zinzani P; Mannina D; Gozzetti A; Molinari AL; Gentile M; Consoli U; Laurenti L; Arcaini L; Ibatici A; Murru R; Tani M; et alii...